Scott, Aaron J. Song, Eun-Kee Bagby, Stacey Purkey, Alicia McCarter, Martin Gajdos, Csaba Quackenbush, Kevin S. Cross, Benjamin M. Pitts, Todd Choon Tan, Aik Eckhardt, S. Gail Fenton, Hubert Arcaroli, John A. Messersmith, Wells Pharmacodynamic effects of dasatinib on the Src pathway. <p>A) Treatment with dasatinib (0.8 μmol/L) at 0.5h, 1h, 2h, 4h, and 8h significantly reduced the activation of Src, FAK and paxillin at all time points examined in the HCT116 sensitive CRC cell line when compared to control. B) A decrease in Src activity was seen in 1 out of 3 CRC explants treated with dasatinib in the sensitive (CRC036) and resistant CRC explant (CRC027) measured at end of study (day 28). However, in both cases FAK activity appeared to be increased.</p> Src pathway;anti-proliferative activity;72 hours;17 CRC explants;Src expression;dasatinib treatment;CRC explants;G 1 inhibition;baseline increase;anti-tumor effects;Methods CRC cell lines;50 CRC cell lines;tumor growth inhibition;anti-invasive activity;vivo efficacy;G 1 cell cycle arrest;sulforhodamine B;explant mouse model Background Dysregulation;FAK gene expression;17 patient-derived CRC explants;SRB;xenograft mouse model;anti-tumor activity;PDX;patient-derived tumor explant;Conclusion Dasatinib;CRC cell lines;TGI;colorectal cancer cell lines;IC;28 days 2017-11-01
    https://plos.figshare.com/articles/figure/Pharmacodynamic_effects_of_dasatinib_on_the_Src_pathway_/5560561
10.1371/journal.pone.0187173.g004